Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7–8% A1c levels. The TULIP study

Blicklé, J. F.; Hâncu, Nicolae; Piletič, Milivoj; Profozič, Velimir; Shestakova, Marina Vladimirovna; Dain, Marie-Paule; Jacqueminet, S.; Grimaldi, A.

doi:10.1111/j.1463-1326.2008.00980.x

Cited by 49 publications

(30 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 15 RCTs were evaluated encompassing 2837 participants with T2DM meeting the inclusion criteria (Supplementary Table 1) [4,[18][19][20][21][22][23][24][25][26][27][28][29][30][31]. A total of 634 participants from 5 studies were treated with insulin glargine plus metformin; 906 participants from 6 studies received insulin glargine plus a sulphonylurea; and 1297 participants from 9 studies were treated with insulin glargine plus metformin in combination with a sulphonylurea.…”

Section: Studies and Participantsmentioning

confidence: 99%

Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: A pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials

Owens

Traylor

Dain

et al. 2014

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

Section: Studies and Participantsmentioning

confidence: 99%

Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: A pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials

Owens

Traylor

Dain

et al. 2014

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Большинство па-циентов -887 (67,8%) -вводили инсулин на ночь, 326 (24,9%) -утром, и только 12 человек предпочли введение препарата в дневное время. Титрация дозы Лантуса осуществлялась на основании уровня ГПН в соответствии с одной из двух существующих схем -1 раз в неделю или 1 раз в 3 дня [12,14].…”

Section: проблемы эндокринологии 4 2013unclassified

“…Не следует забывать и об обратной зависимости между уровнем HbA 1c на старте инсу-линотерапии и ожидаемой прибавкой массы тела. При более низком уровне HbA 1c в момент инициа-ции инсулинотерапии увеличение веса меньше [13][14][15].…”

Section: проблемы эндокринологии 4 2013unclassified

The effectiveness and safety of the supplementation of therapy with oral hypoglycemic agents by basal insulin in the patients with type 2 diabetes mellitus. Results of the SOLOS observational program

Павлова¹,

Глинкина²

2013

Probl Endokrinol (Mosk)

View full text Add to dashboard Cite

The results of numerous clinical investigations carried out during the last years provide convincing evidence of the high effectiveness and safety of early initiation of insulin therapy. Of special interest are the studies conducted under conditions of real clinical practice. One of them is the Russian SOLOS observational program designed to evaluate the influence of intensification of the treatment of type 2 diabetes mellitus with oral hypoglycemic agents (OHA) supplemented by using insulin glargine in the patients who failed to be adequately compensated by OHA therapy alone. Another objective of this program was to find out the opinion of the patients and physicians about the SoloStar pen employed for injecting insulin glargine. The data concerning 1309 patients at the mean age of 59.5±8.8 years with type 2 diabetes mellitus and the mean duration of the disease 6.9±5.0 years were available for the analysis. The overwhelming majority of the patients presented with severe decompensation of carbohydrate metabolism, the mean fasting blood glucose level being 10.7±2.4 mmol/l and the HbA1c level varying from 7.2 to 18.2% (mean 9.6±1.5%). Supplementation of OHA therapy with insulin glargine caused the significant reduction of the HbA1c level to 8.1±1.0% (p<0.001) within 3 months after the onset of the combined treatment. The HbA1c level fell down to 7.2±0.9% (p<0.001) after 6 months 40.6% of the patients had HbA1c at the level below 7%. Fasting blood glucose levels decreased to 7.4±1.4 mmol/l and 6.3±1.0 mmol/l (p<0.001) at 3 and 6 months after the onset of insulin administration respectively. The number of daytime and nocturnal hypoglycemic episodes under effect of insulin glargine injections significantly decreased by the end of the study. Severe hypoglycemic episodes suffered initially by 8 (0.5%) patients totally disappeared 6 months after the initiation of the combined therapy. Most patients did not need hospitalization after supplementation of OHA treatment with insulin. The results of combined therapy with the use of disposable SoloStar pens were positively assessed by the overwhelming majority of both the patients and the physicians involved in the study.

show abstract

“…Тем не менее, следует учитывать, что чем меньше первоначальная концентрация HbA 1c при старте инсу линотерапии, тем меньше ожидаемая прибавка массы тела [17,30,31,32]. Исходно пациенты, включенные в исследование ORIGIN, характеризовались избыточ ной массой тела (ИМТ 29,8±5,2 кг/м 2 в группе инсулина гларгин и 29,9±5,3 кг/м 2 в группе стандартной терапии).…”

Section: сахарный диабетunclassified

Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study

Бирюкова¹,

Аметов²,

Antsiferov³

et al. 2012

Diabetes mellitus

View full text Add to dashboard Cite

Обсуждаются результаты ORIGIN -многоцентрового исследования в параллельных группах по оценке эффективности применения инсулина гларгин в сравнении со стандартной терапией и терапии полиненасыщенными жирными кислотами ряда омега-3 в сравнении с плацебо в отношении снижения риска сердечно-сосудистой заболеваемости и/или смертности (OR 0.72, p = 0,006)

show abstract

Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7–8% A1c levels. The TULIP study

Abstract: In patients with T2DM with A1c 7-8%, who were previously treated by conventional LM and OAD therapy, adding glargine resulted in greater improvements in glycaemic control vs. intensifying LM.

Cited by 49 publications

References 18 publications

Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: A pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials

Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: A pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials

The effectiveness and safety of the supplementation of therapy with oral hypoglycemic agents by basal insulin in the patients with type 2 diabetes mellitus. Results of the SOLOS observational program

Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study

Contact Info

Product

Resources

About